Sichuan Biokin Pharmaceutical Co., Ltd.: all 149 studies

Page 1 of 2. Open to participants first (104), then studies with results posted, then the rest; newest registration first within each.

• BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based TherapyRecruitingNCT07869836Phase 3
• SI-B036-ST-101 in Advanced/Metastatic Solid TumorsNot yet recruitingNCT07857616Phase 1
• A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid TumorsNot yet recruitingNCT07841925Phase 1/2
• A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid TumorsNot yet recruitingNCT07837622Phase 2
• A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07827261Phase 2
• A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell LymphomaNot yet recruitingNCT07818499Phase 1/2
• A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid TumorsNot yet recruitingNCT07818486Phase 1/2
• A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07797881Phase 2
• A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid TumorsNot yet recruitingNCT07793825Phase 1/2
• A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsNot yet recruitingNCT07788950Phase 2
• A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)Not yet recruitingNCT07783321Phase 3
• A Study of BL-M08D in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid TumorsRecruitingNCT07780318Phase 1/2
• A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid TumorsNot yet recruitingNCT07778862Phase 1
• A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid TumorsNot yet recruitingNCT07769229Phase 2
• A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsRecruitingNCT07763652Phase 1
• A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid TumorsRecruitingNCT07763639Phase 1
• A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingNCT07753226Phase 1
• A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid TumorsNot yet recruitingNCT07744243Phase 1
• A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)Not yet recruitingNCT07739199Phase 2/3
• A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)Not yet recruitingNCT07739186Phase 2/3
• A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanNot yet recruitingNCT07730489Phase 3
• A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)RecruitingNCT07729956Phase 3
• A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsRecruitingNCT07678970Phase 1
• A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast CancerRecruitingNCT07678957Phase 2
• A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung CancerRecruitingNCT07654400Phase 2
• A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)RecruitingNCT07648914Phase 3
• A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)RecruitingNCT07642024Phase 2/3
• A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate CancerNot yet recruitingNCT07641855Phase 2/3
• A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)RecruitingNCT07640789Phase 3
• BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)RecruitingNCT07625644Phase 3
• A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07606612Phase 1
• A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy FailureRecruitingNCT07606599Phase 3
• A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic SyndromesNot yet recruitingNCT07591168Phase 1/2
• A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07591155Phase 1
• A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)RecruitingNCT07582315Phase 3
• A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)RecruitingNCT07554456Phase 2/3
• A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerNot yet recruitingNCT07545460Phase 3
• A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerRecruitingNCT07518173Phase 3
• A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line TreatmentRecruitingNCT07518147Phase 3
• A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)RecruitingNCT07502300Phase 3
• A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsRecruitingNCT07279428Phase 1
• A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT07274852Phase 1
• A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCRecruitingNCT07264816Phase 2
• A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic MalignanciesRecruitingNCT07255898Phase 1
• A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaRecruitingNCT07255872Phase 2/3
• A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT07232524Phase 1
• A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid TumorsRecruitingNCT07232420Phase 1
• A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsRecruitingNCT07232407Phase 1
• A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLCRecruitingNCT07178795Phase 3
• A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction AdenocarcinomaRecruitingNCT07152405Phase 3
• Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsRecruitingNCT07080242Phase 1
• A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid TumorsRecruitingNCT07056556Phase 1
• A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial CancerRecruitingNCT07054567Phase 2
• A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)RecruitingNCT06994195Phase 3
• A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT06986785Phase 2
• A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract CancerRecruitingNCT06978114Phase 2
• A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal CancerRecruitingNCT06962787Phase 2
• A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast CancerRecruitingNCT06957886Phase 3
• A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsRecruitingNCT06954077Phase 1
• A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingNCT06891833Phase 2/3
• A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid ArthritisRecruitingNCT06857227Phase 1
• A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus ErythematosusRecruitingNCT06857214Phase 1
• A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)RecruitingNCT06838273Phase 3
• A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant TherapyRecruitingNCT06830889Phase 3
• A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsNot yet recruitingNCT06755242Phase 1
• A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid MalignanciesRecruitingNCT06718634Phase 1
• A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06718621Phase 1
• A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid TumorsRecruitingNCT06612840Phase 1
• A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingNCT06609187Phase 1
• A Study of BL-B01D1 in Patients With Recurrent GlioblastomaRecruitingNCT06598787Phase 2
• A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid TumorsRecruitingNCT06505824Phase 1
• A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid TumorsRecruitingNCT06503783Phase 1
• A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid TumorsRecruitingNCT06500052Phase 1
• A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingNCT06493864Phase 1
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT06475300Phase 2
• A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06475131Phase 1
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast CancerRecruitingNCT06471205Phase 2
• A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT06469008Phase 1
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT06437522Phase 2
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung CancerRecruitingNCT06437509Phase 2
• A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT06405425Phase 2
• A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06349811Phase 1
• Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsRecruitingNCT06293898Phase 1
• A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic MalignanciesRecruitingNCT06131450Phase 1/2
• A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological MalignanciesRecruitingNCT06066203Phase 1/2
• A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast CancerRecruitingNCT06042894Phase 2
• A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal TumorsRecruitingNCT06031584Phase 1/2
• A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal TumorsRecruitingNCT06008054Phase 2
• A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT06006169Phase 2
• A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological MalignanciesRecruitingNCT05990803Phase 2
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsRecruitingNCT05983432Phase 1
• A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid TumorsRecruitingNCT05965856Phase 2
• A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Phase 2
• A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung CancerRecruitingNCT05924841Phase 2
• A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05924750Phase 1
• A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological MalignanciesRecruitingNCT05803018Phase 1/2
• A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System TumorsRecruitingNCT05785039Phase 2
• Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid TumorsRecruitingNCT05631964Phase 1
• A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingNCT05623982Phase 1/2
• A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingNCT05470348Phase 1

← Sichuan Biokin Pharmaceutical Co., Ltd. overview and focus areas